Related Experiment Videos
[Antinatriuretic effect of sulfinpyrazone]
Schweizerische Medizinische Wochenschrift
|July 7, 1981
Summary
Sulfinpyrazone (Anturan) significantly reduces the body's ability to excrete sodium, potentially worsening fluid retention in patients with heart conditions. This drug interferes with normal renal sodium excretion, posing risks for those with cardiac insufficiency.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Clinical observations suggest sulfinpyrazone may cause edema in patients with borderline compensated cardiac insufficiency.
- Sulfinpyrazone is used for secondary prevention of sudden death post-myocardial infarction.
Purpose of the Study:
- To investigate whether sulfinpyrazone interferes with natriuresis.
- To confirm or refute the suspicion of sulfinpyrazone-induced natriuresis impairment.
Main Methods:
- Two experimental series involving 18 healthy volunteers.
- Administration of a sodium load (5-6g) with and without a single 400mg dose of sulfinpyrazone.
- Measurement of hourly natriuresis over 8-hour periods.
Main Results:
- Sulfinpyrazone significantly reduced sodium excretion by 42% in a randomized trial (p < 0.05).
- Excretion of potassium and creatinine remained unchanged.
- A non-randomized trial also showed significantly lower sodium excretion with sulfinpyrazone.
Conclusions:
- Sulfinpyrazone interferes with normal renal sodium excretion.
- This antinatriuretic effect may be clinically relevant in patients with borderline compensated myocardial insufficiency.
- The study design offers a method to assess antinatriuretic drug side effects.